Fibromyalgia & musculoskeletal pain

Supporting self-management of low back pain with an internet intervention with and without telephone support in primary care (SupportBack 2): a randomised controlled trial of clinical and cost-effectiveness

Lancet RheumatolPublished Randomised controlled trial

Authors' conclusion

The SupportBack internet interventions did not significantly reduce low back pain-related disability over 12 months compared with usual care. They were likely to be cost-effective and safe.

Study context

Population
UK primary care participants with low back pain without serious spinal pathology736 analysed
Participants
825 participants
Comparison
SupportBack internet intervention with or without physiotherapist telephone support, plus usual care, vs usual care
  • Usual caren = 274reference
  • SupportBackn = 275
  • SupportBack with telephone-supportn = 276
Primary endpoint
Low back pain-related disability (RMDQ score), repeated measures model over 12 months
Follow-up
6 weeks, 3 months, 6 months, and 12 months
Methodological detailsthree-arm, 1:1:1 stratified randomisation, parallel economic evaluation, People with lived experience of low back pain involved from the outset
  • Three-arm
  • 1:1:1 stratified randomisation
  • Parallel economic evaluation
  • People with lived experience of low back pain involved from the outset

Primary result

As reported in the abstract

RMDQ over 12 months
Each group vs usual careAdjusted mean difference (97.5% CI)P value
SupportBack
−0.5(−1.2 to 0.2)
P = 0.085
SupportBack with telephone-support
−0.6(−1.2 to 0.1)
P = 0.048

Further findings

Cost-effectiveness

SupportBack dominated usual care (more effective and less costly)
Both interventions likely cost-effective at £20 000 per QALY threshold vs usual care

Safety

Treatment-related serious adverse events

None
0

Original publication

Supporting self-management of low back pain with an internet intervention with and without telephone support in primary care (SupportBack 2): a randomised controlled trial of clinical and cost-effectiveness. Lancet Rheumatol. Published 30 May 2024. doi:10.1016/s2665-9913(24)00086-9

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.